Skip to main content

Table 2 Correlation of GD2 expression to clinicopathologic factors of Chinese melanoma patients

From: Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients

Clinico pathologic feature GD2+ (%) GD2− (%) P valuea
Age (year)
 Median (range) 52.7 ± 13.5 51.1 ± 15.2 0.348
Gender n (%)
 Male 69 (48.6) 74 (50.7) 0.722
 Female 73 (51.4) 72 (49.3)
Ulceration n (%)
 Yes 82 (57.7) 84 (57.5) 0.971
 No 60 (42.3) 62 (42.5)
Thickness
 Median (range) 3.5 (0.5,20.0) 3.7 (0.5,19.5) 0.581
TNM stage n (%)
 I (16) 5 (3.5) 11 (7.5) 0.003
 II (109) 41 (28.9) 68 (46.6)
 III (92) 55 (38.7) 37 (25.3)
 IV (71) 41 (28.9) 30 (20.5)
Metastasis
 Yes 96 (67.6) 67 (45.9) < 0.0001
 No 46 (32.4) 79 (54.1)
Primary site
 Acral (134) 67 (47.2) 67 (45.9) 0.017
 Mucosal (71) 40 (28.2) 31 (21.2)
 CSD (14) 2 (1.4) 12 (8.2)
 Non-CSD (27) 9 (6.3) 18 (12.3)
 Unknown primary (42) 24 (16.9) 18 (12.3)
Survival (months)
 Median (95% CI) 31 (34.1,60.1) 47.1 (21.3,40.7) < 0.0001
  1. aFor evaluation of age, the two independent sample t test or one-way ANOVA was used. For evaluation of gender, ulceration, and TNM stage, the chi-square tests or Fisher’s exact tests were used. For evaluation of thickness, Mann-Whitney U tests were used. For evaluation of OS time, Log-rank tests were used